Biological characteristics of the Trypanosoma cruzi Arequipa strain make it a good model for Chagas disease drug discovery
Metadatos
Mostrar el registro completo del ítemEditorial
Elsevier
Materia
Arequipa strain Benznidazole Chagas disease Chemotherapy Drug discovery Trypanosoma cruzi
Fecha
2022-09-09Referencia bibliográfica
Rubén Martín-Escolano, María José Rosales, Clotilde Marín, Biological characteristics of the Trypanosoma cruzi Arequipa strain make it a good model for Chagas disease drug discovery, Acta Tropica, Volume 236, 2022, 106679, ISSN 0001-706X, [https://doi.org/10.1016/j.actatropica.2022.106679]
Patrocinador
Alfonso Martin Escudero Foundation Junta de Andalucia A-CTS-383-UGR18Resumen
Trypanosoma cruzi, the causative agent of Chagas disease (CD), is a genuine parasite with tremendous genetic
diversity and a complex life cycle. Scientists have studied this disease for more than 100 years, and CD drug
discovery has been a mainstay due to the absence of an effective treatment. Technical advances in several areas
have contributed to a better understanding of the complex biology and life cycle of this parasite, with the aim of
designing the ideal profile of both drug and therapeutic options to treat CD. Here, we present the T. cruzi Arequipa
strain (MHOM/Pe/2011/Arequipa) as an interesting model for CD drug discovery. We characterized acutephase
parasitaemia and chronic-phase tropism in BALB/c mice and determined the in vitro and in vivo benznidazole
susceptibility profile of the different morphological forms of this strain. The tropism of this strain makes it
an interesting model for the screening of new compounds with a potential anti-Chagas profile for the treatment of
this disease.